Combination cancer therapy with bis(thiohydrazide) amide compounds
AssigneeSynta Pharmaceuticals Corp.
InventorsThomas A. Dahl, Matthew McLeod
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2; and a bis(thiohydrazide amide) compound in an amount between about 1473 μmol/m2 and about 1722 μmol/m2.
Claims10
A method of treating a human with ovarian cancer comprising the step of co-administering to the human over three to five weeks:
- paclitaxel or a paclitaxel analogue in an amount of between about 243 μmol/m2 to 315 μmol/m2;
- and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2, wherein the bis(thiohydrazide amide) is represented by the following Structural Formula:
- or a pharmaceutically acceptable salt thereof.
A method of treating a human with cancer, comprising intravenously administering to the human in a four week period, three equal weekly doses of the paclitaxel in an amount of about 94 μmol/m2 and a bis(thiohydrazide amide) represented by the following Structural Formula:
- or a pharmaceutically acceptable salt thereof in an amout of about 532 μmol/m2, wherein the cancer is ovarian cancer.
Dependencies are inferred from the claim text.